AI drug developer Insilico Medicine has returned to the Hong Kong public markets with an updated IPO prospectus, targeting about $292 million in proceeds. The submission marks the company’s fourth bid to list on the Hong Kong Stock Exchange, and comes after a year that included a $123 million oversubscribed Series E, an expanded $100M AI drug discovery R&D and licensing collaboration with Eli Lilly, and Phase 2a clinical data for its lead idiopathic pulmonary fibrosis candidate being published in Nature Medicine.
#advertisement
…
…
